Takeda Pharmaceutical Co. Ltd. Announces Exclusive License And Option Agreement With Natrogen For Development Of Natura-Alpha For Inflammatory Bowel Disease

Published: Dec 19, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSAKA, Japan & DEERFIELD, Ill. & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (“Takeda”) and Natrogen Therapeutics International, Inc. (“Natrogen”) jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen’s Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis (UC).

Help employers find you! Check out all the jobs and post your resume.

Back to news